Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors [Phase I and Clinical Pharmacology]

Conclusion This is the first report of AZD1775 single-agent activity in patients carrying BRCA mutations. Proof-of-mechanism was demonstrated by target modulation and DNA damage response in paired tumor biopsies.

http://jco.ascopubs.org/cgi/content/short/33/30/3409?rss=1

Source: Journal of Clinical Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Do, Wilsker, Ji, Zlott, Freshwater, Kinders, Collins, Chen, Doroshow, Kummar Tags: Phase I and Clinical Pharmacology Source Type: research